https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Follow-Up Study Confirms Omlyclo Biosimilarity to Xolair in Treatment of CSU

Follow-Up Study Confirms Omlyclo Biosimilarity to Xolair in Treatment of CSU

The biosimilar showed similar efficacy, pharmacokinetics, pharmacodynamics, safety, quality of life, and immunogenicity in patients with chronic spontaneous urticaria (CSU).

administrator

Related Articles